Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : Geron Corp. -- Ignore unavailable to you. Want to Upgrade?

To: BulbaMan who wrote (867)	1/23/1998 2:32:00 PM
From: Winston Kim	Read Replies (1) \| Respond to of 3579

Who cares? Looking @ the chart GERN is doing the exact same thing it did in August when it ran from 6 to 17....Period to digest all the news...then go down...If it follows pattern should hit 11 next week or the week after...The longs will realize that holding this stock for the next 10 years is not worth it...Yes, great discovery....but, what can you do for me now...I am growing older by the minute...a product?? higher revenues? profits?...

To: BulbaMan who wrote (867)	1/23/1998 5:12:00 PM
From: Haolin Ni	Read Replies (2) \| Respond to of 3579

>The details of many biotech partnership deals are not made public because one or both parties consider such details business secret< Hi, Marty, I don't know it is due to your ignorance or you want cheat yourself or fellow investors. It is the rule the every company must report the income and as discribed in the 10Q of the GERN last Q. GERN lose $2.3 millions. Its revenues from collaborative agreements are $2.2 millions. However, its agreement with kyowa Hakko will expire in April, 1998 (I need find out how much Kyowa Hakko give GERN every month) and with Pharmacia & Upjohn will expire in Jan. 2000. Company could not estimate to be received from sale diagnostic products. Therefore, it must find new revenue to support its operation since it burn out over 2 million every three months and had only $25 million assets left which come from the IPO or other sources. GERN has $4.6 million liability. You will see whether there is new revenue come from Boehringer in next Q 10Q. It may not survive after next year if company could not generate new money through sign collaborate agreement. On ther other hand, GERN release every bit good news and don't release the quarterly finacial repor since it lose money from 1990. Today GERN give another news (Company profie, I did not see any company release such news, This is another great discovery by GERN) to pop up the price. It is easy to belive they got nothing from Boehringer since it did not say so. Good luck!